MYNZ Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2024Q3

250.00K

+37.61%

-4.400

-71.79%

Estimates Revision

The market is revising No Change the revenue expectations for Mainz Biomed N.V. (MYNZ) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -22.37%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-22.37%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast MYNZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MYNZ is 14.00 USD with a low forecast of 14.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

14.00

Averages

14.00

High

14.00

Current: 0.000

Low

14.00

Averages

14.00

High

14.00

Maxim Group

Michael Okunewitch

Strong Buy

Initiates

$14

2025-02-14

Reason

Maxim Group

Michael Okunewitch

Price Target

$14

2025-02-14

Initiates

Strong Buy

Reason

Maxim initiated coverage of Mainz Biomed with a Buy rating and $14 price target.

Valuation Metrics

The current forward P/E ratio for Mainz Biomed NV (MYNZ.O) is -0.55, compared to its 5-year average forward P/E of -2.52. For a more detailed relative valuation and DCF analysis to assess Mainz Biomed NV 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.52

Current PE

-0.55

Overvalued PE

0.10

Undervalued PE

-5.13

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

54.54

Current PS

10.62

Overvalued PS

133.95

Undervalued PS

-24.87

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

MYNZ News & Events

Events Timeline

No data

News

2.0

01-05Globenewswire

Mainz Biomed Launches eAArly DETECT 2 Clinical Study Covering 2,000 Patients

7.5

2025-12-02Globenewswire

Mainz Biomed Integrates ColoAlert® Test into DoctorBox Platform in Germany

7.5

2025-12-02Newsfilter

Mainz Biomed Partners with DoctorBox to Launch ColoAlert Test in Germany

People Also Watch

Frequently Asked Questions

What is Mainz Biomed NV (MYNZ) stock price today?

The current price of MYNZ is 1.18 USD — it has increased 0.43 % in the last trading day.

What is Mainz Biomed NV (MYNZ)'s business?

Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.

What is the price predicton of MYNZ Stock?

What is Mainz Biomed NV (MYNZ)'s revenue for the last quarter?

Mainz Biomed NV revenue for the last quarter amounts to 214.76K USD, decreased % YoY.

What is Mainz Biomed NV (MYNZ)'s earnings per share (EPS) for the last quarter?

Mainz Biomed NV. EPS for the last quarter amounts to -0.27 USD, decreased % YoY.

What changes have occurred in the market's expectations for Mainz Biomed NV (MYNZ)'s fundamentals?

How many employees does Mainz Biomed NV (MYNZ). have?

Mainz Biomed NV (MYNZ) has 19 emplpoyees as of January 09 2026.

What is Mainz Biomed NV (MYNZ) market cap?

Today MYNZ has the market capitalization of 10.69M USD.